Revenue down 75.1% and NPAT down 78.2% on non-recurring 2022 land sales

Management attributes the decline to the absence of one-off high-value land sales that boosted the prior comparable, compounded by the residential downturn that began in 2022. Annolyse's historical baseline classifies revenue, PBT, and NPAT growth as below normal (recent means around zero), so the deterioration is real even after acknowledging the lumpy prior period.

Operating cash flow fell 76.9% to NZ$2.5m. Despite that, cash on the balance sheet grew to NZ$45.0m from NZ$15.1m a year earlier, total liabilities shrank to NZ$1.3m, and equity edged up 1.6% to NZ$305.3m. PBT margin of 59.1% sits within the historical range, and NPAT margin of 42.2% sits at the upper edge - what changed is volume, not unit economics.

HY22 included one-off high-value land sales and was flagged as an acquisition period in the supplied overlays. The 75.1% revenue decline therefore overstates the underlying run-rate change. The decline is nevertheless real against Annolyse's recent baseline (3-period revenue growth mean of 0.3%, range -22.2% to 40.3%), so investors should anchor on the volume reset rather than the percentage gap.

Working-capital absorption sat at the upper edge of the historical range at NZ$2.1m, against a historical mean of -NZ$0.6m (i.e., typically a small release). Receivable days extended from 5.7 to 55.9. The receivable-days level itself remains within Annolyse's historical range of 5.7-76.1, so this looks like settlement timing on residual land sales rather than structural deterioration - but it does dampen cash conversion this half.

The balance sheet strengthened, not weakened. Cash tripled to NZ$45.0m, liabilities are negligible at NZ$1.3m, and NTA at cost is NZ$1.05 per share. With no debt and a small trade book, CDI retains optionality to acquire land counter-cyclically and to absorb a further period of soft volumes without dilution or distress.

The shape context supplied (HY22 was 70.9% of FY22 revenue and 73.4% of FY22 NPAT) confirms that the prior year was heavily first-half weighted, which makes HY23 a particularly weak comparison rather than a clean run-rate. Annualising HY23 implies roughly NZ$23.7m of revenue, against FY22's NZ$67.1m - the release does not support an FY23 path that recovers FY22 levels.

Management commentary anticipates moderating sentiment into 2024 and points to commercial property diversification as a supplementary revenue stream, but neither claim is sized. The gap matters because there is no disclosure here that lets an investor model second-half settlements.

PBT margin (59.1%) is within the supplied historical range, NPAT margin (42.2%) is at the upper edge, and the 28.0% effective tax rate sits at the lower edge of the historical range - none of which suggest the result was flattered. There are no discontinued operations or non-recurring items disclosed.

Cash quality is softer than NPAT implies. FCF-to-NPAT was 43.9% versus 47.2% prior, and the NZ$2.1m working-capital absorption is the opposite of the historical release pattern (mean -NZ$0.6m). The receivable-days swing from 5.7 to 55.9 means HY23 collection lagged invoicing materially more than HY22. The headline NZ$45.0m cash balance therefore reflects prior-period receipts more than HY23 trading; if HY23 receivables do not convert in the second half, FY23 operating cash flow could underperform NPAT.

This briefing cannot assess section ASP trends, contracted-but-unsettled volumes, or land-bank carrying values because those disclosures are not provided in the release.